CTOs on the Move

Nurix Therapeutics

www.nurixtx.com

 
Nurix Therapeutics discovers drugs that harness the body`s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.nurixtx.com
  • 1700 Owens Street Suite 205
    San Francisco, CA USA 94158
  • Phone: 415.660.5320

Executives

Name Title Contact Details

Funding

Nurix Therapeutics raised $120M on 03/12/2020
Nurix Therapeutics raised $160.4M on 03/04/2021

Similar Companies

Octave Bioscience

Octave is developing a comprehensive, first-in-class Care Management Platform.

Young Living Essential Oils

Young Living Essential Oils is a Lehi, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zalicus

Zalicus is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Crinetics

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing`s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company`s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.

Levant Technologies

Levant Technologies is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.